463 related articles for article (PubMed ID: 15560948)
1. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
[TBL] [Abstract][Full Text] [Related]
2. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres.
Jaganathan KS; Rao YU; Singh P; Prabakaran D; Gupta S; Jain A; Vyas SP
Int J Pharm; 2005 Apr; 294(1-2):23-32. PubMed ID: 15814228
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
Gupta RK; Chang AC; Siber GR
Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
[TBL] [Abstract][Full Text] [Related]
4. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
5. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines.
Waeckerle-Men Y; Groettrup M
Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953
[TBL] [Abstract][Full Text] [Related]
6. Formulation aspects of biodegradable polymeric microspheres for antigen delivery.
Tamber H; Johansen P; Merkle HP; Gander B
Adv Drug Deliv Rev; 2005 Jan; 57(3):357-76. PubMed ID: 15560946
[TBL] [Abstract][Full Text] [Related]
7. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
8. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Elamanchili P; Diwan M; Cao M; Samuel J
Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402
[TBL] [Abstract][Full Text] [Related]
9. Aspects of the design and delivery of microparticles for vaccine applications.
Jenkins PG; Coombes AG; Yeh MK; Thomas NW; Davis SS
J Drug Target; 1995; 3(1):79-81. PubMed ID: 7655826
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
[TBL] [Abstract][Full Text] [Related]
11. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells.
Wischke C; Borchert HH; Zimmermann J; Siebenbrodt I; Lorenzen DR
J Control Release; 2006 Sep; 114(3):359-68. PubMed ID: 16889866
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies.
Mundargi RC; Srirangarajan S; Agnihotri SA; Patil SA; Ravindra S; Setty SB; Aminabhavi TM
J Control Release; 2007 May; 119(1):59-68. PubMed ID: 17331611
[TBL] [Abstract][Full Text] [Related]
13. Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination.
Oster CG; Kim N; Grode L; Barbu-Tudoran L; Schaper AK; Kaufmann SH; Kissel T
J Control Release; 2005 May; 104(2):359-77. PubMed ID: 15907586
[TBL] [Abstract][Full Text] [Related]
14. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
16. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
Jain S; O'Hagan DT; Singh M
Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
18. In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation.
Peyre M; Fleck R; Hockley D; Gander B; Sesardic D
Vaccine; 2004 Jun; 22(19):2430-7. PubMed ID: 15193406
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
20. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation.
Wischke C; Zimmermann J; Wessinger B; Schendler A; Borchert HH; Peters JH; Nesselhut T; Lorenzen DR
Int J Pharm; 2009 Jan; 365(1-2):61-8. PubMed ID: 18812217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
